News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

A three-drug therapy targeting breast cancer could double the amount of time patients live without the disease progressing, a trial has found. Researchers praised the “huge breakthrough” as ...

Neoadjuvant therapy is the therapy you receive before your main treatment or surgery. Their research suggested that neoadjuvant therapy with a combination of ribociclib and letrozole could be an ...

A powerful three-drug therapy for aggressive ... of PIK3CA mutant HR-positive breast cancer. The results show that inavolisib in combination with palbociclib and fulvestrant significantly improves ...

Mei Wei, MD, an oncologist specializing in breast ... CDK4/6 inhibitors plus aromatase inhibitors as the first line of therapy has significantly improved the PFS and the overall survival as ...

Hormone therapy (also called ... women with low-risk breast cancer who (by patient choice and physician recommendation) did not receive chemotherapy, 12-year survival is excellent regardless ...

NICE has recommended moving Novartis’ Kisqali (ribociclib ... advanced breast cancer who had previous endocrine therapy. This compared patients treated with Kisqali plus fulvestrant with ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

BriaCell (BCTX) Therapeutics announces new survival ... of therapy. The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients who received the Bria-IMT regimen plus ...

A three-drug combination targeting aggressive advanced breast cancer could potentially ... protein – as well as the hormone ...